{name}
{subtitle}
Placebo-controlled Study Comparing Niraparib Plus Pembrolizumab Versus Placebo Plus Pembrolizumab as Maintenance Therapy in Participants With Advanced/Metastatic Non-small Cell Lung Cancer
city
~20 mi. (Gauting, Germany, +151 more cities)
facility
GSK Investigational Site
drug
niraparib, +1 more drug
drug type
immunotherapy, +1 more type
Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Bacillus Calmette-Guerin (BCG) in High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC) (MK-3475-676/KEYNOTE-676)
city
~34 mi. (Munich, Germany, +130 more cities)
facility
Klinikum Rechts der Isar. Technischen Universitaet Muenchen ( Site 0266)
drug
BCG solution, +1 more drug
Adj. Marker-adjusted Personalized Therapy Comparing ET+Ribociclib vs Chemotherapy in Intermediate Risk, HR+/HER2- EBC
city
~34 mi. (Munich, Germany, +3 more cities)
facility
Klinikum der Universität München Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Brustzentrum
biomarker
ER Positive, +2 more biomarkers
drug
hormone therapy, +1 more drug
drug type
hormone therapy, +1 more type
Safety and Efficacy of SGN-LIV1A Plus Pembrolizumab for Patients With Locally-Advanced or Metastatic Triple-Negative Breast Cancer
city
~34 mi. (Munich, Germany, +37 more cities)
facility
Klinikum Rechts der Isar der Technischen Universitat Munchen
biomarker
ER Negative, +2 more biomarkers
drug
ladiratuzumab vedotin, +1 more drug
drug type
chemotherapy, +2 more types
A Study to Evaluate Dostarlimab Plus Carboplatin-paclitaxel Versus Placebo Plus Carboplatin-paclitaxel in Participants With Recurrent or Primary Advanced Endometrial Cancer
city
~64 mi. (Rosenheim, Germany, +144 more cities)
facility
GSK Investigational Site
drug
carboplatin, +3 more drugs
drug type
chemotherapy, +2 more types
Study of Pembrolizumab (MK-3475) in Combination With Adjuvant Chemotherapy With or Without Radiotherapy in Participants With Newly Diagnosed Endometrial Cancer After Surgery With Curative Intent (MK-3475-B21 / KEYNOTE-B21 / ENGOT-en11 / GOG-3053)
city
~66 mi. (Innsbruck, Austria, +176 more cities)
facility
Medizinische Universitaet Innsbruck ( Site 2001)
condition
Endometrial Carcinoma, +1 more condition
drug
chemotherapy, +2 more drugs
drug type
chemotherapy, +2 more types